Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team
15.12.2022 - – Dr. David Gray brings nearly 20 years of preclinical and clinical research and drug development expertise in neurological diseases – – Dr. Spyros Papapetropoulos to depart Vigil to pursue a Chief Executive Officer opportunity – CAMBRIDGE, ... Seite 1